[
  {
    "ts": null,
    "headline": "Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients",
    "summary": "The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.",
    "url": "https://finnhub.io/api/news?id=cd1dcc678f221e9a9dd9e8e12e6c2121f6aed9edece2003400de7d273c796396",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762809600,
      "headline": "Merck’s Heart Pill Slashes Cholesterol Levels in Test Patients",
      "id": 137415864,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.",
      "url": "https://finnhub.io/api/news?id=cd1dcc678f221e9a9dd9e8e12e6c2121f6aed9edece2003400de7d273c796396"
    }
  },
  {
    "ts": null,
    "headline": "Amgen CEO talks trial results of cardiac drug Repatha",
    "summary": "Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more.",
    "url": "https://finnhub.io/api/news?id=26c8db2f1339432d31ed5545ba41f522a4986d33bcea646fec10ad6922437cc2",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762802755,
      "headline": "Amgen CEO talks trial results of cardiac drug Repatha",
      "id": 137448224,
      "image": "https://image.cnbcfm.com/api/v1/image/108223985-2ED1-REQ-111025-MMBBLOCKSHORT.jpg?v=1762818500&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more.",
      "url": "https://finnhub.io/api/news?id=26c8db2f1339432d31ed5545ba41f522a4986d33bcea646fec10ad6922437cc2"
    }
  },
  {
    "ts": null,
    "headline": "Amgen CEO Bob Bradway goes one-on-one with Jim Cramer",
    "summary": "Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more.",
    "url": "https://finnhub.io/api/news?id=e60554bc7dc10eb1a72f18df6ea2ac4c6abd67489b3e666cc00b7fb771ffd22f",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762802508,
      "headline": "Amgen CEO Bob Bradway goes one-on-one with Jim Cramer",
      "id": 137448225,
      "image": "https://image.cnbcfm.com/api/v1/image/108223992-2ED1-REQ-111025-BBLOCK.jpg?v=1762819662&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "Amgen Chairman, President and CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk quarterly results, its recent drug trials, what is ahead for the company and more.",
      "url": "https://finnhub.io/api/news?id=e60554bc7dc10eb1a72f18df6ea2ac4c6abd67489b3e666cc00b7fb771ffd22f"
    }
  },
  {
    "ts": null,
    "headline": "CEO of drugmaker Amgen talks new results from cholesterol drug trial",
    "summary": "Amgen CEO Bob Bradway told CNBC's Jim Cramer about his company's treatment to reduce heart attack risk.",
    "url": "https://finnhub.io/api/news?id=46c8565b1e7de788300bba3d601d8bda9540510006bdb01399e6ccb857b51319",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762799999,
      "headline": "CEO of drugmaker Amgen talks new results from cholesterol drug trial",
      "id": 137448226,
      "image": "https://image.cnbcfm.com/api/v1/image/107390832-1711031881240-gettyimages-1244662987-porzycki-pharmace221110_npGy2.jpeg?v=1762804398&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "Amgen CEO Bob Bradway told CNBC's Jim Cramer about his company's treatment to reduce heart attack risk.",
      "url": "https://finnhub.io/api/news?id=46c8565b1e7de788300bba3d601d8bda9540510006bdb01399e6ccb857b51319"
    }
  },
  {
    "ts": null,
    "headline": "Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?",
    "summary": "Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.",
    "url": "https://finnhub.io/api/news?id=877f405f48fd14d51729b48bb9c43bc2eb55d994dcd1734202be682688a5bfe5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762791660,
      "headline": "Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?",
      "id": 137396561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.",
      "url": "https://finnhub.io/api/news?id=877f405f48fd14d51729b48bb9c43bc2eb55d994dcd1734202be682688a5bfe5"
    }
  },
  {
    "ts": null,
    "headline": "Beat the Market the Zacks Way: Amgen, Ciena, Fair Isaac in Focus",
    "summary": "Amgen, Ciena, and Fair Isaac shine as Zacks' proven stock-ranking strategies continue to outperform amid market uncertainty.",
    "url": "https://finnhub.io/api/news?id=5a1e43fa9faae07072c9d5a098e1828e86527e55c0664d6c3767e62561d8eb1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762780920,
      "headline": "Beat the Market the Zacks Way: Amgen, Ciena, Fair Isaac in Focus",
      "id": 137394960,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen, Ciena, and Fair Isaac shine as Zacks' proven stock-ranking strategies continue to outperform amid market uncertainty.",
      "url": "https://finnhub.io/api/news?id=5a1e43fa9faae07072c9d5a098e1828e86527e55c0664d6c3767e62561d8eb1d"
    }
  },
  {
    "ts": null,
    "headline": "2 Cash-Producing Stocks to Research Further and 1 We Find Risky",
    "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
    "url": "https://finnhub.io/api/news?id=caca98906d361ccaf3061ae36615f78d789141dadb1f4937d342a21d460c85e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762749766,
      "headline": "2 Cash-Producing Stocks to Research Further and 1 We Find Risky",
      "id": 137394998,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.",
      "url": "https://finnhub.io/api/news?id=caca98906d361ccaf3061ae36615f78d789141dadb1f4937d342a21d460c85e3"
    }
  }
]